Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Thalidomide for the Treatment of Cytopenias of Patients With Low Risk Myelodysplastic Syndromes

NCT00455910 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT00455910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00455910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Thalidomide for the Treatment of Cytopenias of Patients With Low Risk Myelodysplastic Syndromes
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2003
Completion date
March 31, 2007
Enrollment
112
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes